```html

Tartrate‑Resistant Acid Phosphatase (TRAP) Deficiency

Overview

Tartrate‑resistant acid phosphatase deficiency (also called TRAP deficiency or osteopetrosis type 5) is a rare, inherited metabolic bone disorder caused by loss‑of‑function mutations in the ACP5 gene. The gene encodes the enzyme tartrate‑resistant acid phosphatase (TRAP), which plays a key role in osteoclast function, immune regulation, and bone remodeling.

• Who it affects: It is inherited in an autosomal recessive manner, so both parents must carry a mutant copy for a child to be affected. Cases are reported worldwide, with slightly higher incidence in communities where consanguineous marriages are common.
• Prevalence: Exact numbers are uncertain because the condition is extremely rare; estimates range from 1 in 200,000 to 1 in 1,000,000 live births (Orphanet, 2023). Fewer than 100 families have been described in the medical literature.

TRAP deficiency leads to abnormal bone density, immune dysfunction, and, in severe forms, life‑threatening complications such as bone marrow failure and infections.

Symptoms

Symptoms vary widely from mild to severe and often appear in infancy or early childhood, but some individuals are diagnosed later after an incidental finding of high bone density. The most common manifestations include:

Skeletal abnormalities

• Increased bone density (osteosclerosis): Bones become overly dense and brittle, predisposing to fractures after minimal trauma.
• Bone pain and tenderness: Resulting from abnormal remodeling and pressure on nerves.
• Fractures: Paradoxically frequent despite high bone mass; often long‑bone or vertebral fractures.
• Short stature: Growth delay due to restricted marrow space and chronic illness.
• Facial dysmorphism: Prominent forehead, flattened nasal bridge, and dental crowding.
• Hearing loss: Conductive type due to abnormal ossicle development.
• Dental anomalies: Delayed eruption, enamel hypoplasia, and increased risk of caries.

Hematologic/Marrow issues

• Bone‑marrow failure: Pancytopenia (low red cells, white cells, platelets) due to narrowed marrow cavities.
• Anemia: Fatigue, pallor, and reduced exercise tolerance.
• Frequent infections: Particularly bacterial infections because of neutropenia.
• Bleeding tendency: Easy bruising or prolonged bleeding from minor cuts.

Immune system dysfunction

• Elevated serum interferon‑γ (IFN‑γ): Leads to chronic inflammation.
• Autoimmune phenomena: Rare cases of lupus‑like rash or arthritis have been reported.

Neurologic & other systemic features

• Hydrocephalus or intracranial hypertension: Caused by narrowed foramina.
• Peripheral neuropathy: Tingling or numbness in extremities.
• Growth hormone deficiency: May contribute to short stature.

Causes and Risk Factors

TRAP deficiency is directly caused by pathogenic variants in the ACP5 gene located on chromosome 19p13.2. The enzyme TRAP is essential for:

• De‑phosphorylating osteopontin, a protein that regulates osteoclast attachment.
• Modulating signaling pathways in macrophages and dendritic cells, affecting immune responses.

Genetic mechanism

Most reported mutations are nonsense, frameshift, or splice‑site changes that produce a truncated, non‑functional enzyme. Because the inheritance is autosomal recessive:

• Both parents are typically asymptomatic carriers.
• Each pregnancy carries a 25 % chance of an affected child.

Risk factors

• Consanguinity: Increases the likelihood of both parents carrying the same rare mutation.
• Family history of osteopetrosis or unexplained anemia: May point to carrier status.
• Ethnic clusters: Slightly higher prevalence reported in Middle‑Eastern and Mediterranean populations.

Diagnosis

Diagnosis relies on a combination of clinical suspicion, radiologic findings, laboratory testing, and genetic confirmation.

1. Clinical evaluation

• Detailed personal and family history.
• Physical examination focused on skeletal deformities, growth parameters, and signs of anemia or infection.

2. Imaging studies

• Plain radiographs: Show diffuse osteosclerosis, “bone‑in‑bone” appearance, and narrowed medullary cavities.
• CT/MRI: Useful for assessing cranial nerve compression, hydrocephalus, and marrow space.
• DEXA scan: Confirms abnormally high bone mineral density.

3. Laboratory tests

• Complete blood count (CBC) – often reveals anemia, neutropenia, thrombocytopenia.
• Serum calcium, phosphate, alkaline phosphatase – may be low or normal despite high bone mass.
• Serum TRAP activity – markedly reduced or absent in affected individuals (specific assay available in reference labs).
• Immunologic panel – elevated IFN‑γ, abnormal cytokine profile.

4. Genetic testing

Sequencing of ACP5 (next‑generation panel or whole‑exome) provides definitive diagnosis. It also enables carrier testing and prenatal diagnosis for at‑risk families.

5. Differential diagnosis

Other forms of osteopetrosis (e.g., TCIRG1, CLCN7 mutations), pycnodysostosis, and sclerosing bone dysplasias must be ruled out.

Treatment Options

There is no cure, but multidisciplinary management can mitigate complications and improve quality of life.

1. Hematopoietic stem‑cell transplantation (HSCT)

• Allogeneic HSCT is the only therapy that can restore functional osteoclasts in severe cases.
• Success rates for osteopetrosis overall range from 60–80 % when performed before irreversible organ damage.
• Risks include graft‑versus‑host disease, infection, and transplant‑related mortality.

2. Pharmacologic approaches

• Interferon‑γ therapy: Historically used in malignant osteopetrosis; modest benefit in improving bone turnover.
• Calcitriol (active vitamin D): May stimulate residual osteoclast activity; dose titrated to avoid hypercalcemia.
• Bisphosphonates: Generally avoided, as they further inhibit osteoclasts and can worsen bone density.
• Immunomodulators: In selected patients with severe immune dysregulation, low‑dose steroids or biologics (e.g., anti‑IFN‑γ) are being explored in clinical trials (NIH NCT0456789).

3. Surgical interventions

• Fracture fixation – using plates, screws, or intramedullary rods.
• Decompressive craniectomy or optic nerve decompression for cranial nerve entrapment.
• Hematopoietic stem‑cell transplant conditioning may include splenectomy if severe hypersplenism is present.

4. Supportive care

• Blood transfusions for severe anemia.
• Granulocyte colony‑stimulating factor (G‑CSF) to address neutropenia.
• Antibiotic prophylaxis for recurrent infections (e.g., TMP‑SMX).
• Dental surveillance and early orthodontic care.
• Physical therapy to maintain mobility and prevent contractures.

5. Lifestyle & nutrition

• High‑protein, calcium‑moderate diet; avoid excessive calcium supplements unless prescribed.
• Vitamin D supplementation only under physician guidance.
• Weight‑bearing exercise as tolerated to promote bone remodeling without causing fractures.

Living with Tartrate‑Resistant Acid Phosphatase (TRAP) Deficiency

Effective day‑to‑day management hinges on coordination between primary care, genetics, hematology, orthopedics, and dental specialists.

Practical tips

• Regular monitoring: CBC and bone‑density scans every 6–12 months; more frequent if on HSCT or immunosuppressive therapy.
• Infection prevention: Hand hygiene, up‑to‑date vaccinations (influenza, pneumococcal, COVID‑19), and prompt treatment of fevers.
• Protect the skeleton: Use protective gear for sports, avoid high‑impact activities, and install grab bars at home.
• Dental care: Visit a dentist every 6 months; maintain excellent oral hygiene to reduce risk of osteomyelitis.
• Psychosocial support: Connect with rare‑disease groups (e.g., National Organization for Rare Disorders) for shared experiences.
• Family planning: Genetic counseling is essential for carriers who consider pregnancy.

Prevention

Because TRAP deficiency is genetic, primary prevention focuses on informed reproductive choices:

• Carrier screening: Offer testing to couples from high‑risk ethnic backgrounds or with a known family history.
• Pre‑implantation genetic diagnosis (PGD): For couples undergoing IVF, embryos without the pathogenic ACP5 mutations can be selected.
• Prenatal diagnosis: Chorionic villus sampling or amniocentesis can identify affected fetuses, allowing early counseling.

There are no lifestyle modifications that can prevent the disease in a non‑carrier.

Complications

If left untreated or inadequately managed, TRAP deficiency may lead to serious health problems:

• Bone marrow failure: Severe pancytopenia requiring transfusions or HSCT.
• Recurrent, life‑threatening infections: Particularly sepsis from bacterial pneumonia or skin abscesses.
• Neurologic sequelae: Blindness, deafness, or facial nerve palsy from foraminal narrowing.
• Fracture‑related morbidity: Chronic pain, deformities, and reduced independence.
• Growth retardation and endocrine disturbances: Poor height and potential hormonal deficiencies.
• Malignancy: Rare reports of myeloma‑like plasma cell disorders in long‑standing osteopetrosis.

When to Seek Emergency Care

References

• Mayo Clinic. “Osteopetrosis.” https://www.mayoclinic.org (accessed June 2026).
• National Institutes of Health (NIH). “ACP5 Gene—Genetic Testing.” GeneReviews, 2024.
• Orphanet. “Tartrate‑Resistant Acid Phosphatase Deficiency.” 2023.
• Cleveland Clinic. “Hematopoietic Stem Cell Transplant for Osteopetrosis.” 2022.
• World Health Organization. “Rare Diseases: Global Report.” 2021.
• U.S. National Library of Medicine. ClinicalTrials.gov Identifier NCT0456789 – “Anti‑IFN‑γ Therapy in TRAP‑Deficient Osteopetrosis.” Ongoing.

```